Cardiac Troponin I Predicts Elevated B-type Natriuretic Peptide in Patients Treated with Anthracycline-Containing Chemotherapy
| العنوان: | Cardiac Troponin I Predicts Elevated B-type Natriuretic Peptide in Patients Treated with Anthracycline-Containing Chemotherapy |
|---|---|
| المؤلفون: | Tetsuro Yokokawa, Takafumi Ishida, Yasuchika Takeishi, Akiomi Yoshihisa, Daiki Yaegashi, Makiko Miyata, Tomofumi Misaka, Masayoshi Oikawa, Kazuhiko Nakazato |
| المصدر: | Oncology. 98:653-660 |
| بيانات النشر: | S. Karger AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, Cancer Research, medicine.medical_specialty, Anthracycline, medicine.drug_class, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Natriuretic Peptide, Brain, Troponin I, Natriuretic peptide, medicine, Humans, Anthracyclines, In patient, 030212 general & internal medicine, Cardiotoxicity, Chemotherapy, business.industry, Cancer, General Medicine, Middle Aged, musculoskeletal system, medicine.disease, Oncology, Echocardiography, 030220 oncology & carcinogenesis, cardiovascular system, Cardiology, Female, business, Blood sampling |
| الوصف: | Background: Anthracycline is used to treat various types of cancer; however, cardiotoxicity negatively affects patient prognosis. Objectives: The aim of the present study was to investigate serial changes in levels of cardiac troponin I (TnI) and B-type natriuretic peptide (BNP) in patients treated with anthracycline-containing therapy. Methods: 91 consecutive cancer patients planned for anthracycline treatment were enrolled and followed up for 12 months. All patients underwent echocardiography and blood sampling at baseline, 3, 6, and 12 months. Results: The patients were divided into two groups based on their TnI level during the follow-up period: the elevated TnI group (TnI ≥0.03 ng/mL; n = 37) and the normal TnI group (n = 54). In the elevated TnI group, the TnI levels increased at 3 and 6 months, but they returned to within normal range at 12 months after anthracycline administration. Unlike TnI, the BNP levels began to increase after 6 months, and remained increased at 12 months. The occurrence of cancer therapeutics-related cardiac dysfunction was higher in the elevated TnI group than in the normal TnI group. When we set the cut-off value of TnI at 0.029 ng/mL, sensitivity and specificity to predict an elevated BNP level of more than 100 pg/mL were 90 and 63%, respectively. Multivariate logistic regression analysis revealed that elevated TnI was an independent predictor of elevated BNP levels. Conclusion: Elevated TnI was an independent predictor for the development of BNP increase. The different characteristics of TnI and BNP should be considered when managing patients treated with anthracycline-containing therapy. |
| تدمد: | 1423-0232 0030-2414 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cacdde84c73475ac6cc1b6b354797f6Test https://doi.org/10.1159/000507585Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....3cacdde84c73475ac6cc1b6b354797f6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14230232 00302414 |
|---|